Aflibercept in combination with Folfiri in patients with metastatic colorectal cancer: cost-effectiveness based on velour best efficacy subgroup post-hoc analysis
M Echave, I Oyagüez, MJ Lamas, M Rubio… - Value in …, 2015 - valueinhealthjournal.com
Objectives To estimate the incremental cost per life-year gained (LYG) of aflibercept in
combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) …
combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) …
Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer
C Pericay, C Frías, A Abad, MJ Lamas… - … : Organo Oficial de …, 2014 - europepmc.org
Objectives To estimate the incremental cost per life-year gained (LYG) of aflibercept in
combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) …
combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) …
Aflibercept in combination with FOLFIRI as first-line chemotherapy in patients with metastatic colorectal cancer (mCRC): a phase II study (FFCD 1302)
A Lapeyre-Prost, S Pernot, J Sigrand… - Clinical Colorectal …, 2020 - Elsevier
Abstract Background FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin)+ aflibercept
improves median overall survival (OS) and progression-free survival (PFS) in patients with …
improves median overall survival (OS) and progression-free survival (PFS) in patients with …
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain
J Feliu, I Díez de Corcuera, JL Manzano… - Clinical and …, 2017 - Springer
Purpose In the VELOUR study, aflibercept+ FOLFIRI regimen resulted in improved survival
in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of …
in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of …
A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI
I Chau, F Joulain, SU Iqbal, J Bridgewater - BMC cancer, 2014 - Springer
Background The VELOUR study demonstrated a survival benefit for FOLFIRI+ aflibercept
versus FOLFIRI+ placebo in metastatic colorectal cancer (mCRC) patients who progressed …
versus FOLFIRI+ placebo in metastatic colorectal cancer (mCRC) patients who progressed …
[HTML][HTML] Aflibercept plus FOLFIRI for second-line treatment of metastatic colorectal cancer: observations from the global aflibercept safety and health-related quality-of …
RP Riechelmann, V Srimuninnimit, R Bordonaro… - Clinical colorectal …, 2019 - Elsevier
Background The objectives of this study were to evaluate the safety profile of aflibercept and
health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) …
health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) …
Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program
M Salgado Fernandez, MT Perez Hoyos… - Expert Opinion on …, 2015 - Taylor & Francis
Objective: Aflibercept increased overall survival with acceptable tolerability in metastatic
colorectal cancer (mCRC) when it was used in combination with FOLFIRI after progression …
colorectal cancer (mCRC) when it was used in combination with FOLFIRI after progression …
A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and …
I Chau, F Joulain, S Iqbal… - Annals of Oncology, 2013 - annalsofoncology.org
Background: The VELOUR study demonstrated a significant survival benefit for aflibercept
(ziv-aflibercept in the USA) plus FOLFIRI (5-fluorouracil-leuocovorin-irinotecan) versus …
(ziv-aflibercept in the USA) plus FOLFIRI (5-fluorouracil-leuocovorin-irinotecan) versus …
Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment
P Ge, N Wan, X Han, X Wang, J Zhang… - Frontiers in …, 2022 - frontiersin.org
Background: Metastatic colorectal cancer (mCRC) imposes a heavy tumor burden
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …
[HTML][HTML] Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer …
J Tabernero, E Van Cutsem, R Lakomý… - European journal of …, 2014 - Elsevier
Purpose The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in
combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved …
combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved …
相关搜索
- cost effectiveness aflibercept in combination
- prognostic groups aflibercept and folfiri
- treatment outcomes aflibercept and folfiri
- cost effectiveness folfiri in patients
- treatment of patients aflibercept in combination
- cost effectiveness combination with folfiri
- treatment of patients combination with folfiri
- cost effectiveness folfiri in the treatment
- cost effectiveness treatment of patients